BRIGE: Reprogramming tumor associated macrophages: Engineering polymer surface properties to discriminately deliver drugs
BRIGE:重编程肿瘤相关巨噬细胞:工程聚合物表面特性以有区别地输送药物
基本信息
- 批准号:1227867
- 负责人:
- 金额:$ 17.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:Standard Grant
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-01 至 2015-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PI: Bratlie, KaitlinProposal Number: 1227867Intellectual MeritMacrophages can be activated classically or alternatively to produce pro-inflammatory or pro-angiogenic molecules, respectively. Tumor associated macrophages (TAMs) are alternatively activated cells that promote tumor growth. TAMs can be reprogrammed through drug delivery to classically activated macrophages, which kill neoplastic cells. Discriminatory drug delivery to TAMs presents a very attractive cancer therapeutic in which alternatively activated macrophages could be reconditioned to destroy malignant cells. Therefore, our long term goal is to deliver drugs discriminately to TAMs that will promote tumor regression. The objective of this proposal, which is the out next step in pursuit of that goal, is to determine what surface properties allow for selective targeting to alternatively activated macrophages. This proposal theorizes that discriminatory targeting to TAMs can be achieved through engineering microparticle compositions such that phagocytosis is preferentially enhanced in alternatively activated macrophages. The rationale for the proposed research is that, once it is known what material parameters influence selective phagocytosis in alternatively activated macrophages, new and innovative strategies for designing anti-cancer therapeutics will be uncovered. This hypothesis will be tested through the following aims: 1) Determine what microparticle properties result in the facilitation of selectivephagocytosis in vivo; 2) Engineer polymeric systems to determine the best conditions for selectively delivering reprogramming drugs to TAMs. The proposed research is expected to contribute in-depth understanding of how best to engineer the drug delivery vehicle such that TAMs are reprogrammed to destroy cancerous cells. This work will generate information on what polymer parameters and particle configurations augment drug delivery to macrophages. This contribution is significant, because it is expected to revolutionize anti-cancer drug delivery through exploiting polymer properties and particle compositions to discriminately target TAMs, such that they produce molecules that are toxic to tumors.Broader ImpactsDeveloping novel anti-cancer therapeutics will have a tremendous impact on cancer patients. In addition, this research is expected to be able to improve knowledge pertaining to how to best engineer a drug delivery vehicle to target alternatively activated macrophages. This has the potential to positively impact people stricken with cardiovascular disease, people on antiretroviral therapy, and patients with autoimmune diseases. This research and the goals contained within are ideal for actively involving students - from high school to graduate students - in the lab. Through collaboration with the Program for Women in Science and Engineering (PWSE), high school girls will be introduced to this research. In addition, an undergraduate currently working on this project has been recruited through the PWSE program. We live in a wireless world in which large amount of communications are digital. To take full advantage of this modern world, the research done in this proposal, along with the knowledge obtained from the literature, will be combined to form an iPad/iPhone app. This app will disseminate the knowledge gleaned through this study to all types of students, and may be particularly impactful for students in areas of the country/world in which these sorts of classes and professionals are not readily available.
主要研究者:Bratlie,Kaitlin提案编号:1227867智力优点巨噬细胞可以被经典地或替代地激活,以分别产生促炎或促血管生成分子。肿瘤相关巨噬细胞(TAM)是促进肿瘤生长的交替活化细胞。TAM可以通过药物递送重新编程为经典活化的巨噬细胞,其杀死肿瘤细胞。区别性药物递送到TAM呈现出非常有吸引力的癌症治疗,其中可替代地活化的巨噬细胞可以被修复以破坏恶性细胞。因此,我们的长期目标是有区别地将药物递送到将促进肿瘤消退的TAM。该提案的目的是追求这一目标的下一步,是确定什么样的表面特性允许选择性靶向替代活化的巨噬细胞。该提议从理论上证明,可以通过工程化微粒组合物来实现对TAM的区分性靶向,使得吞噬作用在交替活化的巨噬细胞中优先增强。这项研究的基本原理是,一旦知道什么材料参数会影响选择性激活的巨噬细胞的吞噬作用,就可以发现设计抗癌疗法的新的创新策略。该假设将通过以下目的进行测试:1)确定何种微粒性质导致体内选择性吞噬的促进; 2)工程化聚合物系统以确定选择性地将重编程药物递送至TAM的最佳条件。 这项拟议中的研究预计将有助于深入了解如何最好地设计药物递送载体,使TAM重新编程以摧毁癌细胞。这项工作将产生什么样的聚合物参数和颗粒配置增强药物输送到巨噬细胞的信息。这一贡献是重要的,因为它有望通过利用聚合物特性和颗粒组成来有区别地靶向TAM,从而产生对肿瘤有毒性的分子,从而彻底改变抗癌药物的递送。更广泛的影响开发新的抗癌疗法将对癌症患者产生巨大的影响。此外,这项研究预计能够提高有关如何最好地设计药物递送载体以靶向替代活化的巨噬细胞的知识。这有可能对心血管疾病患者、接受抗逆转录病毒治疗的患者和自身免疫性疾病患者产生积极影响。 这项研究和其中包含的目标是理想的积极参与学生-从高中到研究生-在实验室。通过与科学和工程妇女方案(PWSE)的合作,将向高中女生介绍这项研究。此外,目前正在从事该项目的一名本科生已通过PWSE计划招募。 我们生活在一个无线的世界,其中大量的通信是数字的。为了充分利用这个现代化的世界,本提案中所做的研究,沿着从文献中获得的知识,将结合形成一个iPad/iPhone应用程序。该应用程序将向所有类型的学生传播通过本研究收集的知识,并可能对这些课程和专业人员不容易获得的国家/世界地区的学生产生特别的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kaitlin Bratlie其他文献
Kaitlin Bratlie的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kaitlin Bratlie', 18)}}的其他基金
Bratlie 2nd Year Ext
布拉特利第二年分机
- 批准号:
2035016 - 财政年份:2020
- 资助金额:
$ 17.5万 - 项目类别:
Intergovernmental Personnel Award
相似海外基金
Elucidation of tumor development mechanism by immune escape mechanism through metabolic reprogramming of anticancer drug-resistant cancer
通过抗癌药物耐药性癌症的代谢重编程的免疫逃逸机制阐明肿瘤发生机制
- 批准号:
23K18344 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Enhanced Deuterium Metabolic Imaging (DMI) of Metabolic Reprogramming in Brain Tumors
脑肿瘤代谢重编程的增强氘代谢成像 (DMI)
- 批准号:
10593853 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
Project 1: Overcoming therapeutic resistance in pancreatic cancer through epigenetic reprogramming
项目1:通过表观遗传重编程克服胰腺癌的治疗耐药性
- 批准号:
10629063 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
Hypoxic regulation of macrophage migration and function via fibroblast reprogramming in pancreatic cancer
通过胰腺癌成纤维细胞重编程对巨噬细胞迁移和功能的缺氧调节
- 批准号:
10677376 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
"DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"
“DNMT 和 TET1 重编程作为晚期前列腺癌的靶向耐药机制”
- 批准号:
10681632 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
Targeting macrophage reprogramming in glioblastoma
胶质母细胞瘤中靶向巨噬细胞重编程
- 批准号:
10734257 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
Secretory Mitophagy in Cancer Metabolic Reprogramming
癌症代谢重编程中的分泌性线粒体自噬
- 批准号:
10743163 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy
通过合成生物学解码和重编程 T 细胞用于癌症免疫治疗
- 批准号:
10568704 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
Chromunities Drive Transcriptional Reprogramming in Humoral Immunity and B-cell Lymphomas
染色体驱动体液免疫和 B 细胞淋巴瘤中的转录重编程
- 批准号:
10606730 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
Targeting regenerative reprogramming in colorectal cancer
靶向结直肠癌的再生重编程
- 批准号:
10644262 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别: